Retinal Neurovascular Impairment in Patients with Essential Hypertension: An Optical Coherence Tomography Angiography Study

Qingsheng Peng,1,2 Yijun Hu,1,3,4 Manqing Huang,1 Ying Wu,5 Pingting Zhong,1,2 Xinran Dong,1 Qiaowei Wu,1,6 Baoyi Liu,1,6 Cong Li,1 Jinxian Xie,1 Yu Kuang,1 Danqing Yu,5 Honghua Yu,1 and Xiaohong Yang1

1Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China
2Shantou University Medical College, Shantou, China
3Aier School of Ophthalmology, Central South University, Changsha, China
4Aier Institute of Refractive Surgery, Refractive Surgery Centre, Guangzhou Aier Eye Hospital, Guangzhou, China
5Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China
6Southern Medical University, Guangzhou, China

Correspondence: Xiaohong Yang, Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, No. 106, Zhongshan Second Road, Guangzhou 510080, China; syyangxh@scut.edu.cn.
Honghua Yu, Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, No. 106, Zhongshan Second Road, Guangzhou 510080, China; yuhonghua@gdph.org.cn.
Danzing Yu, Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, No. 106, Zhongshan Second Road, Guangzhou 510080, China; gdydq100@126.com.

QP, YH, and MH contributed equally to the work presented here and should therefore be regarded as equivalent authors.

Received: December 7, 2019
Accepted: May 19, 2020
Published: July 29, 2020

PURPOSE. To investigate retinal neurovascular structural changes in patients with essential hypertension.

METHODS. This observational cross-sectional study consisted of 199 right eyes from 169 nondiabetic essential hypertensive patients, divided into groups as follows: group A, 113 patients with hypertensive retinopathy (HTNR); group B, 56 patients without HTNR; and a control group of 30 healthy subjects. Peripapillary retinal nerve fiber layer (RNFL), radial peripapillary segmented (RPC), ganglion cell–inner plexiform layer (GC-IPL), and superficial (SVP) and deep (DVP) vascular plexus density at the macula (6 × 6 mm2) were measured by optical coherence tomography angiography (OCTA).

RESULTS. DVP density was significantly reduced in groups A and B compared to the control group (group A DVP, P = 0.001; group B DVP P = 0.002). GC-IPL, RNFL thickness, and RPC and SVP density in group A were significantly decreased compared to the control group or group B (all P < 0.05). In hypertensive patients, GC-IPL and RNFL thickness were negatively correlated with severity of HTNR (GC-IPL, r = –0.331, P < 0.001; RNFL, r = –0.583, P < 0.001) and level of home blood pressure monitoring (HBPM) (GC-IPL, r = –0.160, P = 0.050; RNFL, r = –0.282, P = 0.001) and were positively correlated with SVP (GC-IPL, r = 0.267, P = 0.002; RNFL, r = 0.361, P < 0.001) and RPC density (GC-IPL, r = 0.298, P < 0.001; RNFL, r = 0.663, P < 0.001). Among subjects with grade 2 or 3 retinopathy, the superior RNFL was significantly thinner in patients with high HBPM level than in those with normal HBPM level (grade 2, P = 0.016; grade 3, P = 0.006).

CONCLUSIONS. Reduction of retinal vessel density and RNFL thickness is observed in patients with HTNR and is inversely associated with level of HBPM.

Keywords: hypertensive retinopathy, optical coherence tomography angiography, retinal nerve fiber layer, home blood pressure monitoring

Citation: Peng Q, Hu Y, Huang M, et al. Retinal neurovascular impairment in patients with essential hypertension: An optical coherence tomography angiography study. Invest Ophthalmol Vis Sci. 2020;61(8):42. https://doi.org/10.1167/iovs.61.8.42
Hypertension affects more than 40% of adults over the age of 25 years worldwide. Systemic complications, particularly cardiovascular complications, have been the main causes of mortality. In a survey of hypertension complications, 44% of the investigated population had been diagnosed with retinopathy. Previous studies have reported that subjects with hypertensive retinopathy (HTNR) had the same risk of cardiovascular disease mortality as patients with diabetes. It has been suggested that HTNR could serve as a valuable indicator of severe hypertension complications requiring more aggressive antihypertensive treatments. For this reason, fundus examinations are essential in patients with hypertension; in fact, in the 2018 guidelines of the European Society of Hypertension, funduscopy examination was recommended for patients with grade 2 or grade 3 hypertension.

Hypertension-mediated organ damage (HMOD) has been considered to be a strong risk factor for cardiovascular and cerebral diseases, as well as a marker of preclinical or asymptomatic cardiovascular diseases. Peripheral capillary rarefaction as evidence of HMOD can be observed in nailfold, conjunctival, and skin capillaroscopy or laser Doppler flowmetry. Because optical coherence tomography angiography (OCTA) provides robust microvascular structure quantification, rarefaction can also be detected on the retina. Previous studies have reported a decrease in perfusion in the macular area along with ganglion cell-inner plexus layer (GC-IPL) thinning in essential hypertension. Perfusion reduction in the retinal was also observed in hypertensive patients with poorly controlled blood pressure (BP). These early studies demonstrated that OCTA could be a supportive imaging method for the detection of HTNR and HMOD in hypertensive patients.

Although decreased retinal perfusion in patients with hypertension has been previously investigated, there is little evidence regarding the change of perfusion in retinal vessels in the peripapillary area, which are believed to interact with the retinal nerve fiber layer (RNFL) as part of the cerebral neurovascular unit; whether or not the neurovascular impairment appears simultaneously is unknown. Also, few studies have considered the impact of different stages of HTNR on retinal OCTA features. Moreover, despite the fact that antihypertensive treatment has been proven to be an influence of retinal microcirculation, such effect was not considered in previous studies about retinal vessel density in patients with hypertension. Furthermore, the possible association between BP control and the OCTA neurovascular features in hypertensive patients had yet to be investigated. In this study, we conducted a prospective survey of patients with essential hypertension, aiming to discover the changes of retinal perfusion and thickness and their association with BP control in eyes with or without HTNR.

**METHOD**

**Study Participants**

This was a prospectively planned observational cross-sectional study that included a total of 199 right eyes from 169 hypertensive patients—group A, 113 patients diagnosed with HTNR; group B, 56 patients without retinopathy; 30 healthy controls—from the cardiology clinic of Guangdong Provincial People’s Hospital in Guangzhou from January 2019 to January 2020. Subjects recruited were local Chinese patients between the ages of 40 and 70 years who had been diagnosed with essential hypertension. Excluded from the study were participants with moderate or severe refractive error (higher than +3.0 diopeter or lower than −3.0 diopeter), history of glaucoma, history of ophthalmic surgery or retinal diseases, secondary causes of hypertension, BP higher than 160/100 after treatment, HbA1c higher than 6.1%, cardiac functional classification higher than grade 1, hypertensive complications other than retinopathy, coronary heart disease, stroke history, neurodegenerative diseases, migraine, or sleep apnea. Patients with arrhythmia or mental disorders or who were undergoing hormone therapies were also excluded for health and safety reasons. The study was approved by the ethics committee of Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Science, and was carried out in accordance to the tenets of the Declaration of Helsinki. Each participant was informed of the study and provided full consent in writing.

**Examination Procedures**

Clinical records of the patients’ antihypertensive medications, blood tests, and office blood pressure measurements (OBPMs) were reviewed. Lifestyle risk factors and demographic data such as age, smoking history, drinking behavior, home blood pressure monitoring (HBPM) for 3 months, and psychological states were collected using interviewer-administered questionnaires. All patients’ OBPMs were taken before their participation using the same type of sphygmomanometer (HBPM-9020; Omron, Kyoto, Japan) as in the clinic. Each OBPM was taken after a participant had been seated comfortably in the waiting room for 5 minutes and was recorded as the average of three consecutive measurements with a deviation of <10 mm Hg. Data for each patient’s HBPM were collected through questionnaires every 2 weeks for the previous 3 months. All patients were taught to correctly operate the HBPM device (Omron 7130/7133/8102k) and were instructed to record their HBPM results each morning and evening. The cut-off HBPM level was set at 135/85 mm Hg (normal, HBPM < 135/85 mm Hg; high, HBPM ≥ 135/85 mm Hg). All patients who participated were taking antihypertension medications, including angiotensin channel enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) monotherapy, calcium channel blocker (CCB) monotherapy, and low-dose ACEI/ARB and CCB combined therapy. The height of each subject was measured using a wall-mounted measuring tape, and weight was measured with a digital scale. Body mass index (BMI) was calculated using the formula proposed by Keys et al. (BMI = body weight [kg] / height squared [m]). Smoking history was defined as those who had smoked in the past versus those who had not.

**Ocular Examinations**

Each participant underwent visual acuity measurement, autorefractometry (HRK-7000A Auto Refractor; Huvitz, Inc., Anyang-si, South Korea), non-contact tonometry (TX-20 Full Auto Tonometer; Canon, Inc., Tokyo, Japan), slit-lamp examination, and fundus photography (TRC-NW8 non-mydriatic retinal camera, Topcon, Tokyo, Japan; D7500 DSLR camera, Nikon, Tokyo, Japan). Diagnosis and grading of HTNR were performed by two ophthalmologists specialized in retinal diseases using indirect fundoscopy and fundus photography; grading was based on Keith–Wagener–Barker and...
Retinal Neurovascular Impairment in Hypertension

RESULTS

Details of the HTNR gradings are shown in Table 1. Demographic characteristics, antihypertension medications, and OCTA parameters of the three groups are shown in Table 2. ANCOVA of the OCTA parameters for the various antihypertensive therapies and stages of HTNR are shown in Table 3. Partial correlation analyses between OCTA and hypertension parameters are shown in Table 4. Best-corrected vision acuity (BCVA), SE, intraocular pressure (IOP), BMI, smoking history, and drinking behavior among the three groups were not significantly different (all \( P > 0.05 \)). Antihypertension medications and hypertension duration between group A and group B were not significantly different (all \( P > 0.05 \)).

Comparison of SVP and DVP Vessel Density

Significant differences were found in both SVP (\( P = 0.001 \)) and DVP (\( P = 0.001 \)) vessel density among the three groups. In subgroup analysis, there were significant decreases of DVP vessel density in both group A (51.0 ± 5.6%, \( P = 0.002 \)) and group B (51.8 ± 5.6%, \( P = 0.001 \)) compared to normal controls (54.2 ± 5.5%). The parafocal DVP were also significantly lower in both group A and group B.

Table 1. Grading of Hypertensive Retinopathy in the Three Groups

| Features                                      | Mitchell–Wong | Keith–Wager–Barker | With Retinopathy (N = 113) | Without Retinopathy (N = 56) | Normal Control (N = 30) |
|-----------------------------------------------|---------------|-------------------|----------------------------|-----------------------------|-------------------------|
| Mild generalized retinal arteriolar narrowing | None          | 0                 | 0                          | 56                          | 30                      |
| Definite focal narrowing and arteriovenous nipping | 1              | 36                | 0                          | 0                           |                         |
| Signs of grade 2 retinopathy plus retinal hemorrhages, exudates, and cotton wool spots | 2              | 51                | 0                          | 0                           |                         |
| Severe grade 3 retinopathy plus papilledema   | 3              | 26                | 0                          | 0                           |                         |

Keith-Wager-Barker and Mitchell-Wong are two grading systems for hypertensive retinopathy, the grading systems are mainly based on retinal fundoscopy and photography.

Optical Coherence Tomography and Angiography

OCTA examination (RTVue-XR Avanti OCT System; Optovue, Inc., Fremont, CA, USA) with 6 × 6-mm² macula HD scan and 4.5 × 4.5 mm² disk HD scan mode (6 × 6-mm² macula HD scan and disk HD scan mode are the high definition modes distinguished from the normal scan modes. Normal scans filmed with the RTVue-XR Avanti OCT System do not have the same image parameters described in the context.) was performed on each participant. The RTVue-XR Avanti uses split-spectrum amplitude-decorrelation angiography. The central wavelength of the system was set at 840 nm. The device can generate 304 × 304 scans in 2.9 seconds with a scanning speed at 70 kHz. The operating software of the RTVue-XR Avanti utilizes a projection-resolved OCTA algorithm to distinguish the superficial plexus; the RNFL and GC-IPL layers were automatically segmented. Parameters included RNFL and GC-IPL thickness and vessel density of the superficial vascular plexus (SVP), deep vascular plexus (DVP), and radial peripapillary capillaries (RPCs). Macular and peripapillary areas were further distinguished automatically, and capillary density was measured with a built-in feature called large-vessel masking, which removes vessels with a diameter of ≥3 pixels, approximately ≥33 μm for the 4.5-mm AngioVue optic disc (AngioDisc) scans (Figs. 1, 2).

Extended Follow-Up for Exclusion

Because some information acquired in the study came from questionnaires, we set up an extended follow-up procedure. Patients with irregular clinical follow-up visits were asked to participate in a follow-up examination 1 month after completing the last questionnaire. In the follow-up confirmation process, five normal controls were excluded due to newly found hypertension, and 11 hypertensive patients were excluded because of changes in their antihypertensive treatment.

**Retinopathy Grades**

- **Mild generalized retinal arteriolar narrowing**
  - Mitchell–Wong: None
  - Keith–Wager–Barker: 0
- **Definite focal narrowing and arteriovenous nipping**
  - Mitchell–Wong: Mild
  - Keith–Wager–Barker: 1
- **Signs of grade 2 retinopathy plus retinal hemorrhages, exudates, and cotton wool spots**
  - Mitchell–Wong: Moderate
  - Keith–Wager–Barker: 2
- **Severe grade 3 retinopathy plus papilledema**
  - Mitchell–Wong: Severe
  - Keith–Wager–Barker: 4

**Statistical Analysis**

Normally distributed continuous variables were presented as mean ± SD; \( \chi^2 \) tests were used to compare nonparametric variables among the three groups. Independent \( t \)-tests were applied to compare the duration of hypertension between the two hypertensive groups. Tests for homogeneity of variance were applied to the OCTA data, including RNFL thickness, RPC density, and SVP and DVP density. ANOVA was used to compare the continuous variables. After baseline parameters showed no significance among the groups, multiple comparisons (Bonferroni) were carried out in post hoc analysis. After adjusting for age, BMI, spherical equivalent (SE), and duration of hypertension, analysis of covariance (ANCOVA) was used to investigate the impact of HTNR, various medication methods, and high HBPM levels on OCTA parameters among the hypertensive patients. Finally, partial correlation analyses were carried out to search for correlations between retinal vessel density and thickness and between OCTA parameters and HTNR grades (0, 1, 2, or 3) and HBPM levels, after adjusting for age, gender, hypertension duration, BMI, refractive error, smoking history, drinking behavior, and antihypertensive medications.
FIGURE 1. Layer identification and automatic segmentation using the AngioVue 2.0. (A) RNFL layer and its topographic map. (B) The 4.5 × 4.5-mm² peripapillary area was divided into temporal, nasal, superior, and inferior quadrants, and each quadrant was then separated into two embedding areas. (C) A 6 × 6-mm² macula area was split into segments based on distance to fovea; the parafoveal area was a concentric circle 1 mm to the fovea, and the perifoveal area was a concentric circle 1.5 mm to the parafovea. (D) The RPC layer was segmented into arteriovenous vessels (E) and capillaries (F). Vessel density was calculated separately.

FIGURE 2. Superior RNFL thickness in patients with well-controlled or poorly controlled blood pressure in different grades of hypertensive retinopathy.
### Table 2. Demographics of the Three Groups and ANCOVA Results for OCTA Parameters

| Demographic                        | With Retinopathy | Without Retinopathy | Normal Controls | $P^{1}$ | $P^{2}$ | $P^{3}$ | $P^{4}$ |
|------------------------------------|------------------|---------------------|-----------------|---------|---------|---------|---------|
| Participants (n)                   | 115              | 56                  | 30              |         |         |         |         |
| Females (n)                        | 51               | 35                  | 15              | 0.104   |         |         |         |
| Smoking history (n)                | 10               | 6                   | 19              | 1.000   |         |         |         |
| Drinking behavior (n)              | 5                | 6                   | 3               | 0.257   |         |         |         |
| Normal HBPM level                  | 59               | 30                  | 30              | <0.001* |         |         |         |
| ACEI/ARB                           | 34               | 18                  | 0               | 0.002*  | 0.785*  |         |         |
| CCB                                | 53               | 20                  | 0               | <0.001* | 0.167*  |         |         |
| ACEI/ARB and CCB                   | 26               | 18                  | 0               | 0.001*  | 0.203*  |         |         |
| BCVA (logMAR), mean ± SD           | -0.01 ± 0.06     | -0.02 ± 0.05        | -0.01 ± 0.03    | 0.872   | 1.000   | 1.000   | 1.000   |
| SE (diopters), mean ± SD           | -0.3 ± 2.0       | -0.1 ± 1.9          | 0.1 ± 1.7       | 0.650   | 0.990   | 0.636   | 0.781   |
| IOP (mm Hg), mean ± SD             | 16.0 ± 3.1       | 15.0 ± 3.8          | 14.7 ± 2.3      | 0.512   | 1.000   | 0.636   | 0.826   |
| Age (y), mean ± SD                 | 54.1 ± 11.1      | 52.4 ± 10.1         | 53.6 ± 9.2      | 0.759   | 0.816   | 1.000   | 1.000   |
| HTN duration (y), mean ± SD        | 7.3 ± 8.0        | 6.6 ± 6.2           | 6.7 ± 8.0       | 0.480** |         |         |         |
| BMI (kg/m²), mean ± SD             | 24.4 ± 3.3       | 24.8 ± 2.5          | 24.1 ± 1.9      | 0.470   | 1.000   | 0.700   |
| Systolic BP, mean ± SD             | 135 (130–149)    | 136 (127–147)       | 117 (110–122)   | <0.001* | 1.000   | <0.001* | <0.001* |
| Diastolic BP, mean ± SD            | 85 (80–95)       | 85 (79–93)          | 75 (65–81)      | <0.001* | 1.000   | <0.001* | <0.001* |
| RNFL thickness (µm), mean ± SD     | 110.3 ± 13.0     | 122.5 ± 7.5         | 123.3 ± 9.8     | <0.001* | 0.006*  | 0.001*  | 0.369   |
| Mean                               | 135.1 ± 19.8     | 150.7 ± 14.6        | 149.2 ± 12.6    | <0.001* | 0.005*  | 0.002*  | 0.677   |
| Superior                           | 139.0 ± 21.3     | 159.0 ± 14.2        | 160.3 ± 13.3    | <0.001* | 0.006*  | 0.001*  | 0.468   |
| Inferior                           | 77.3 ± 11.2      | 85.4 ± 8.7          | 84.6 ± 10.6     | <0.001* | 0.001*  | 0.002*  | 1.000   |
| Nased                              | 89.1 ± 15.2      | 95.5 ± 11.6         | 101.0 ± 16.6    | <0.001* | 0.022*  | <0.001* | 0.296   |
| GC-IPL thickness (µm), mean ± SD   | 97.0 ± 6.7       | 101.2 ± 5.5         | 102.0 ± 6.9     | <0.001* | <0.001* | 0.001*  | 1.000   |
| Systolic BP, mean ± SD             | 48.9 ± 2.8       | 50.2 ± 2.0          | 50.8 ± 1.7      | <0.001* | 0.006*  | 0.001*  | 0.784   |
| Capillary                          | 57.9 ± 4.0       | 59.7 ± 2.7          | 60.1 ± 2.0      | <0.001* | 0.008*  | 0.007*  | 1.000   |
| Superior hemifield                 | 56.8 ± 3.9       | 58.8 ± 2.3          | 59.6 ± 2.2      | <0.001* | <0.001* | 0.001*  | 0.982   |
| Mean                               | 49.6 ± 3.9       | 50.2 ± 3.1          | 51.1 ± 3.6      | 0.001*  | 0.035*  | 0.002*  | 0.553   |
| Mean                              | 51.9 ± 4.8       | 52.7 ± 3.3          | 54.0 ± 3.8      | 0.002*  | 0.257   | 0.002*  | 0.178   |
| Mean                              | 51.0 ± 5.6       | 51.8 ± 5.6          | 54.2 ± 5.5      | 0.001*  | 1.000   | 0.002*  | 0.001*  |
| Mean                              | 55.8 ± 3.5       | 54.8 ± 3.8          | 57.3 ± 4.2      | 0.005*  | 1.000   | 0.006*  | 0.011   |

IQR, interquartile range; RE, refraction error; IOP, intraocular pressure.

* Statistically significant differences at $P < 0.05$.

† Nonparametric demographics of the three groups were analyzed using $\chi^2$ test.

‡ Continuous demographics and OCTA parameters of the three groups were analyzed using one-way ANOVA.

§ Obtained using post hoc Bonferroni correction between patients without retinopathy and normal controls.

|| Obtained using post hoc Bonferroni correction between patients with retinopathy and normal controls.

| Comparison of RPC Vessel Density |
|----------------------------------|

Significant differences were found in general, capillary, superior hemifield, and inferior hemifield RPC density among the three groups (general, $P < 0.001$; capillary, $P < 0.001$; superior hemifield, $P = 0.001$; inferior hemifield, $P < 0.001$). In the subgroup analysis, the general, capillary, superior hemifield, and inferior hemifield RPC densities in group A were significantly lower than in both group B (general, $P = 0.001$; capillary, $P = 0.006$; superior hemifield, $P = 0.008$; inferior hemifield, $P < 0.001$) and the control group (general, $P < 0.001$; capillary, $P = 0.001$; superior hemifield, $P = 0.007$; inferior hemifield, $P = 0.001$). No significance in RPC vessel density was found between Group B and the control group (all $P > 0.05$).

### Comparison of RNFL and GC-IPL Thickness

There were significant differences in mean, superior, inferior, temporal, and nasal RNFL and GC-IPL thickness among the three groups (all $P < 0.05$). In the subgroup analysis, greater RNFL thinning was found in group A compared to normal controls in all of the sectors (all $P < 0.05$) or compared to group B (all $P < 0.05$). Greater GC-IPL thinning was also found in group A compared to both group B ($P < 0.001$) and the control group ($P = 0.001$).

In patients with HTNR, the RNFL thinning observed was most significant in the superior quadrant in patients with grade 2 HTNR (high HBPM, 129.7 ± 20.1 µm; normal HBPM, 142.8 ± 12.5 µm; $P = 0.015$) or grade 3 HTNR (high HBPM, 116.1 ± 9.5 µm; normal HBPM, 125.8 ± 6.3 µm; $P = 0.006$) in combination with high HBPM (Fig. 2).

### ANCOVA of Antihypertensive Medications and HTNR Grades

In the ANCOVA model regarding all hypertensive patients, patients under monotherapies were shown to have lower
Retinal Neurovascular Impairment in Hypertension

### Table 3. ANCOVA Parameter Estimates of Antihypertension Medications and HTNR Grades

| Reference          | Comparing Group | Parameters | \( \beta \) | 95% CI            | \( P \) |
|--------------------|-----------------|------------|-------------|------------------|--------|
| ACEI/ARB & CCB     | ACEI/ARB        | SVP (%)    | -1.569      | -2.756 to -0.383 | 0.010* |
|                    | Parafoveal SVP (%) | -1.303     | -2.867 to -0.343 | 0.012* |
|                    | DVP (%)          | -1.751     | -3.722 to 0.261 | 0.088 |
|                    | Parafoveal DVP (%) | -0.527     | -2.274 to 1.220 | 0.552 |
|                    | General RPC (%)  | -0.420     | -1.492 to 0.652 | 0.440 |
|                    | Segmented RPC (%) | -0.802     | -1.898 to 0.206 | 0.151 |
|                    | RNFL (μm)        | 1.907      | -3.210 to 7.024 | 0.463 |
|                    | GC-IPL (μm)      | -0.695     | -3.641 to 2.251 | 0.642 |
| ACEI/ARB & CCB     | CCB             | SVP (%)    | -1.201      | -2.293 to -0.110 | 0.031* |
|                    | Parafoveal SVP (%) | -1.750     | -3.068 to -0.433 | 0.010* |
|                    | DVP (%)          | -2.360     | -4.192 to -0.528 | 0.012* |
|                    | Parafoveal DVP (%) | -1.655     | -3.127 to -0.184 | 0.028 |
|                    | General RPC (%)  | -0.577     | -1.564 to 0.409 | 0.250 |
|                    | Segmented RPC (%) | -0.702     | -1.610 to 0.206 | 0.129 |
|                    | RNFL (μm)        | 0.585      | -4.123 to 5.293 | 0.806 |
|                    | GC-IPL (μm)      | -3.545     | -6.026 to -1.064 | 0.005* |
| HTNR grade 3       | HTNR grade 2     | RNFL (μm)  | 8.601       | 3.703 to 13.449  | 0.001* |
|                    | GC-IPL (μm)      | 3.010      | 0.159 to 5.879  | 0.048* |
|                    | SVP (%)          | 0.706      | -0.505 to 2.287  | 0.209 |
|                    | DVP (%)          | 0.272      | -2.313 to 2.856  | 0.836 |
|                    | General RPC (%)  | 0.092      | -1.142 to 1.327  | 0.882 |
| HTNR grade 3       | HTNR grade 1     | RNFL (μm)  | 17.275      | 11.780 to 22.770 | <0.001* |
|                    | GC-IPL (μm)      | 5.030      | 1.475 to 8.586  | 0.006* |
|                    | SVP (%)          | 2.233      | 0.666 to 3.799  | 0.006* |
|                    | DVP (%)          | 1.430      | -1.470 to 4.330  | 0.331 |
|                    | General RPC (%)  | 2.030      | 0.645 to 3.415  | 0.004* |

Multiple factors, including age, BMI, SE, and HTN duration, were adjusted in the model.

* Statistically significant differences at \( P < 0.05 \).

### Table 4. Partial Correlation Results Between OCTA and Hypertension Parameters

| Correlated Parameters | \( P \) | Coefficient |
|-----------------------|--------|-------------|
| HTNR grading          |        |             |
| RNFL                  | <0.001*| -0.583      |
| Superior RNFL         | <0.001*| -0.526      |
| Inferior RNFL         | <0.001*| -0.535      |
| GC-IPL                | <0.001*| -0.331      |
| HBPM level            |        |             |
| RNFL                  | 0.001* | -0.282      |
| Superior RNFL         | <0.001*| -0.315      |
| GC-IPL                | 0.050* | -0.160      |
| RPC                   | 0.036* | -0.178      |
| Mean RNFL thickness   |        |             |
| Segmentated RPC       | <0.001*| 0.549       |
| SVP                   | <0.001*| 0.361       |
| DVP                   | 0.240  | 0.100       |
| Superior RNFL thickness |       |             |
| Segmentated RPC       | <0.001*| 0.535       |
| SVP                   | 0.002* | 0.262       |
| DVP                   | 0.854  | 0.016       |
| GC-IPL thickness      |        |             |
| Segmentated RPC       | 0.011* | 0.221       |
| SVP                   | 0.002* | 0.267       |
| DVP                   | 0.214  | 0.110       |
| Systolic OBPM          |        |             |
| RPC                   | 0.535  | 0.054       |
| SVP                   | 0.611  | 0.044       |
| DVP                   | 0.037* | -0.238      |
| RNFL                  | 0.217  | -0.107      |
| GC-IPL                | 0.832  | -0.018      |

* Statistically significant differences at \( P < 0.05 \).

Mean SVP and parafoveal SVP vessel density than patients taking ACEI/ARB and CCB combined therapy (all \( \beta < 0; \text{all } P < 0.05 \)) after adjusting for age, BMI, SE, and hypertension duration. Patients taking only CCB also had significantly lower mean DVP and parafoveal DVP density (all \( \beta < 0; \text{all } P < 0.05 \)). General RPC, SVP density, RNFL, and GC-IPL thickness in patients with grade 3 retinopathy was significantly lower than in patients with grade 1.
The findings from patients with HTNR may also lead to hypertensive impairment begin with altered DVP density. It has been speculated that DVP is a more HTNR, whereas DVP rarefaction was found in both hypertensive groups. In our study, RPC rarefaction and GC-IPL and RNFL reports suggest that retinal vessel rarefaction may be asso-
correlation between RPC volume and RNFL thickness. These OCT studies have also confirmed RNFL thinning as a form of hypertensive retinal damage.30 Yu et al.31 found a close lary hypoperfusion in patients with essential hypertension. RNFL thinning is preceded and caused by retinal peripapil-
density was significantly reduced in patients with essential hypertension. In a cross-sectional observation, Chua et al.17 compared hypertensive patients who had well-controlled BP with those who had poorly controlled BP. The results showed that patients with poorly controlled BP had sparser retinal capil-
lary density. Our study further exhibited the impact of BP control on OCTA parameters. The elevated daily BP caused both neural and vascular retinal impairments. Earlier longitudi-
centration of TNF-α, IL-1β, and IL-6 that can stimulate the formation and generation and HBPM may be more complex than we think and may not be a linear one, as shown by traditional statistics. On the other hand, nonlinear models, such as deep clus-
ter algorithms or radial basis function neural networks, may be more suitable tools for directly extracting useful information from retinal scan images and daily BP monitoring and using it to evaluate BP control and predict HMOD. Prediction of systolic BP with acceptable accuracy using reti-
nal scan imaging via convolutional deep neural networks has been reported.39

To the best of our knowledge, these results for the first time demonstrate the significant effects of various types of antihypertensive therapy on retinal vessels. Activation of the renin–angiotensin system (RAS) is important in increasing peripheral resistance, which induces hypertension and plays a role in cerebrovascular disease.40 CCBs lower blood pressure mainly by reducing intracellular Ca2+ concentrations and relaxing peripheral blood vessels.41 One study reported the possible synergistic effect of CCB with ACEI/ARB on RAS. Combining ACEI/ARB with CCB neutralizes the side effects on the RAS and sympathetic nerve system due to CCB monotherapy; also, the possibility of peripheral edema during CCB monotherapy is reduced.45 On the other hand, the negative sodium balance caused by CCB could enhance the treatment effect of ACEI/ARB.43 Our results further our understanding of the peripheral perfusion improve-
ment resulting from ACEI/ARB and CCB combined therapy. This study identified various effects of antihypertension

retinopathy (all β < 0; all P < 0.05). Among patients with different HTNR grades, the thinning of both RNFL and GC-IPL was more severe in patients with grade 2 or 3 HTNR compared to grade 1 HTNR (all P < 0.05). Details of the ANCOVA results are listed in Table 3.

Correlation Analysis Between OCTA Parameters and Hypertension Data

In the partial correlation analysis, after adjusting for age, gender, BMI, hypertension duration, refractive error, smoking history, drinking behavior, and antihypertensive medications, the severity of HTNR was negatively correlated with mean RNFL thickness (r = −0.583, P < 0.001), superior RNFL thickness (r = −0.526, P < 0.001), inferior RNFL thickness (r = −0.535, P < 0.001), and GC-IPL thickness (r = −0.331, P < 0.001). Level of HBPM was negatively correlated with mean RNFL (r = −0.282, P = 0.001), superior RNFL (r = −0.315, P < 0.001), GC-IPL thickness (r = −0.160, P = 0.050), and RPC density (r = −0.178, P = 0.026). Mean superior RNFL and GC-IPL thickness was found to be positively correlated with RPC, segmented RPC, and SVP density (r = 0.221–0.663; all P < 0.05). Systolic OBPM was found to be correlated with DVP density (r = −0.238, P = 0.037). Details about the correlations are shown in Table 4.

DISCUSSION

Results of our prospective study showed that retinal vessel density was significantly reduced in patients with essential hypertension (with or without HTNR), but RNFL and GC-IPL thinning was only detected in patients with HTNR. We found that retinal capillary rarefaction in the DVP was observed in hypertensive patients, and its severity was independent of the presence of HTNR. This indicates that retinal hypoperfusion exists regardless of hypertensive retinal complication. It implies that retinal hypoperfusion occurs when hypertension has developed. More evidence from future studies is needed to fill in the gaps in our understanding of reti-

nal perfusion change between the prehypertension state and hypertension. On the other hand, we observed RNFL and GC-IPL thinning only in patients with HTNR. Moreover, RNFL thickness was strongly correlated with RPC density. These findings suggest that hypertension causes both retinal vascular and neural damage, and it is very likely that RNFL thinning is preceded and caused by retinal peripapil-
lary hypoperfusion in patients with essential hypertension. A decrease in retinal vessel density has been reported by previous studies using OCTA.11,15,17 In the last decade, OCT studies have also confirmed RNFL thinning as a form of hypertensive retinal damage.30 Yu et al.31 found a close correlation between RPC volume and RNFL thickness. These reports suggest that retinal vessel rarefaction may be associated with neural damage in patients with essential hypert-

ension. In our study, RPC rarefaction and GC-IPL and RNFL thinning were only detected in hypertensive patients with HTNR, whereas DVP rarefaction was found in both hypertensive groups. It has been speculated that DVP is a more sensitive indicator of vascular degeneration than SVP. Our findings support the notion that early variations of retinal hypertensive impairment begin with altered DVP density. The findings from patients with HTNR may also lead to exploring the theory that retinal neural damage occurs along with macular and peripapillary capillary rarefac-
tion in hypertension populations. A similar hypothesis was also proposed in diabetic retinopathy in an OCTA study.18 Recently, it has been proposed that the neurovascular unit (NVU) could be a mechanism for stroke.22 The NVU theory would explain the high prevalence of ischemic stroke in hypertensive patients with HTNR and the fact that structural and functional changes induced by hypertension predispose an individual to ischemic stroke with damage to integral functions of the NVU,32 reflecting common pathophysiology between the two major vascular diseases of hypertension and stroke.1 Cerebral research has found that hypertension-evoked remodeling of cerebral vessels leads to hypoperfu-
sion and exacerbates ischemia-driven pathways, disrupting the integrity of the blood–brain barrier and allowing infiltration of inflammatory cells and cytokines into the brain.34,35 Similar to cerebral NVU findings, RNFL thinning in patients with retinal cotton wool spots has been observed on retina photography.36 In the retina, an extension of cerebral tissue, damage to the NVU caused by hypertension could be visual-
ized in vivo by OCTA, which would provide a fresh perspec-
tive for future research in stroke.

In a cross-sectional observation, Chua et al.17 compared hypertensive patients who had well-controlled BP with those who had poorly controlled BP. The results showed that patients with poorly controlled BP had sparser retinal capil-

lary density. Our study further exhibited the impact of BP control on OCTA parameters. The elevated daily BP caused both neural and vascular retinal impairments. Earlier longitudi-
cohort OCT studies also showed similar results, reporting that prolonged hypertension had a significant impact on the neuroretina, reducing GC-IPL and RNFL thickness.21,37 A recent OCT study also found neurodegeneration in patients with only mildly elevated blood pressure independent of aging.38 Our study further corroborates the suggestion that major hypertension-mediated neural and vascular changes in the retina occur in both the peripapillary and macular areas. Furthermore, the true correlation between neurode-
generation and HBPM may be more complex than we think and may not be a linear one, as shown by traditional statistics. On the other hand, nonlinear models, such as deep clus-
tering algorithms or radial basis function neural networks, may be more suitable tools for directly extracting useful information from retinal scan images and daily BP monitor-
ing and using it to evaluate BP control and predict HMOD. Prediction of systolic BP with acceptable accuracy using reti-
nal scan imaging via convolutional deep neural networks has been reported.39
medications on retinal vessel density, and future studies should further explore antihypertensive medications and retinal vascularity in patients with hypertension.

Based on the results of our study and previous studies, RNFL thinning could serve as an indicator of HTNR, which is considered important evidence of HMOD in clinical practice. Also, the reduction of retinal vessel density, especially DVP density, could be used as an indicator of pre-HTNR damage to the retina. Because GC-IPL and RNFL thickness and retinal vessel density can be accurately quantified by OCTA, OCTA features of hypertensive patients could be important references when setting a patient's target blood pressure. Capillary rarefaction is a possible cause of retinal nerve fiber damage, so OCTA may become the examination of choice to detect retinal capillary rarefaction and determine whether intensified antihypertensive treatment should be applied. Furthermore, because RNFL thinning was more severe in the patients with higher grades of HTNR or poorly controlled BP, the need for more intensive antihypertensive treatment and setting lower blood pressure targets for these patients is evident. Moreover, OCTA examination should be recommended for HTNR patients for regular follow-up to keep track of retinal neurovascular impairments.

This study had some limitations. First, HBPM information was collected by questionnaire, and some patients might not have reported their actual HBPM status; for this reason, ambulatory blood pressure monitoring may be considered in future studies. Second, patients with grade 4 HTNR or relieved grade 4 HTNR were not included in the study due to the lack of such patients in our clinic.

In conclusion, we found that retinal DVP rarefaction appears in the early stage of hypertension. Retinal perfusion and RNFL thickness at the peripapillary area are reduced in patients with hypertensive retinopathy after adjusting for antihypertensive treatments, and the retinal neurovascular impairment is associated with the level of blood pressure control.

Acknowledgments

The authors thank Xiaohong Yang and Honghua Yu for their administrative support, technical support, critical revision, and supervision. The authors also thank the staff of the cardiology clinic at Guangdong Provincial People's Hospital for their assistance in the recruitment and follow-up visits of the participants.

Supported by Guangdong Medical Research Foundation (C2019044; MH) and Project of Investigation on Health Status of Employees in Financial Industry in Guangzhou (Z012014075; MH) and Project of Investigation on Health Status of Employees in Financial Industry in Guangzhou (Z012014075; MH) and Project of Investigation on Health Status of Employees in Financial Industry in Guangzhou (Z012014075; MH). The Science Research Foundation of Aier Eye Hospital Group (AR1909D2 and AM1909D2 to YH) and Science and Technology Program of Guangzhou (2020020049).

Disclosure: Q. Peng, None; Y. Hu, None; M. Huang, None; Y. Wu, None; P. Zhong, None; X. Dong, None; Q. Wu, None; B. Liu, None; C. Li, None; J. Xie, None; Y. Kuang, None; D. Yu, None; H. Yu, None; X. Yang, None

References

1. Leung AA, Daskalopoulou SS, Dasgupta K, et al. Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557–576.
2. Padwal RS, Bieneck A, McAlister FA, Campbell NR, Outcomes Research Task Force of the Canadian Hypertension Education Program. Epidemiology of hypertension in Canada: an update. Can J Cardiol. 2016;32:687–694.
3. Kolman SA, van Sijil AM, van der Sluijs FA, van de Ree MA. Consideration of hypertensive retinopathy as an important end-organ damage in patients with hypertension. J Hum Hypertens. 2017;31:121–125.
4. Ong YT, Wong TY, Klein R, et al. Hypertensive retinopathy and risk of stroke. Hypertension. 2013;62:706–711.
5. Liew G, Wong TY, Mitchell P, Cheung N, Wong JJ. Retinopathy predicts coronary heart disease mortality. Heart. 2009;95:391–394.
6. Aissoupo EK, Papathanassiou M, Nasothimiotou EG, et al. The Keith-Wagener-Barker and Mitchell-Wong grading systems for hypertensive retinopathy: association with target organ damage in individuals below 55 years. J Hypertens. 2015;33:2303–2309.
7. Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophtalmol. 2014;46:260–277.
8. Grosso A, Veglio F, Porta M, Grignolo FM, Wong TY. Hypertensive retinopathy revisited: some answers, more questions. Br J Ophthalmol. 2005;89:1646–1654.
9. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.
10. Greve SV, Blicher MK, Sehestedt T, et al. Effective risk stratification in patients with moderate cardiovascular risk using albuminuria and atherosclerotic plaques in the carotid arteries. J Hypertens. 2015;33:1563–1570.
11. Cordero A, Morillas P, Bertomeu-Gonzalez V, et al. Clustering of target organ damage increases mortality after acute coronary syndromes in patients with arterial hypertension. J Hum Hypertens. 2011;25:600–607.
12. Liu X, He T, Li Y-Z, et al. Alteration in peripheral microcirculation of essential hypertensive patients with different risk stratification. J Am Soc Hypertens. 2016;10:e7.
13. Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018;64:1–55.
14. Lee WH, Park JH, Won Y, et al. Retinal microvascular change in hypertension as measured by optical coherence tomography angiography. Sci Rep. 2019;9:156.
15. Lim HB, Lee MW, Park JH, Kim K, Jo YJ, Kim JY. Changes in ganglion cell-inner plexiform layer thickness and retinal microvasculature in hypertension: an optical coherence tomography angiography study. Am J Ophthalmol. 2019;199:167–176.
16. Pascaud-Prieto J, Burgos-Blasco B, Avila Sanchez-Torija M, et al. Utility of optical coherence tomography angiography in detecting vascular retinal damage caused by arterial hypertension. Eur J Ophthalmol. 2019;30:579–585.
17. Chua J, Chin CWL, Hong J, et al. Impact of hypertension on retinal capillary microvasculature using optical coherence tomographic angiography. J Hypertens. 2019;37:572–580.
18. Cao D, Yang D, Yu H, et al. Optic nerve head perfusion changes preceding peripapillary retinal nerve fibre layer thinning in preclinical diabetic retinopathy. Clin Exp Ophtalmol. 2019;47:219–225.
19. Takayama K, Kaneko H, Ito Y, et al. Novel classification of early-stage systemic hypertensive changes in human retina based on OCTA measurement of chorocapillaries. Sci Rep. 2018;8:15163.
20. Thom S, Stettler C, Stanton A, et al. Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-Scandinavian cardiac outcomes trial substudy. Hypertension. 2009;54:405–408.
21. Lee HM, Lee WH, Kim KN, Jo YJ, Kim JY. Changes in thickness of central macula and retinal nerve fibre layer in severe hypertensive retinopathy: a 1-year longitudinal study. *Acta Ophthal mol Vis Sci.* 2018;59:4299–4306.

22. Hua D, Xu Y, Zeng X, et al. Use of optical coherence tomography angiography for assessment of microvascular changes in the macula and optic nerve head in hypertensive patients without hypertensive retinopathy. *Microvasc Res.* 2020;129:103969.

23. Arnould L, Guenancia C, Azemar A, et al. The EYE-MI pilot study: a prospective acute coronary syndrome cohort evaluated with retinal optical coherence tomography angiography. *Sensory Organs and Vision.* 2018;96:e386–e392.

24. Sprodhuber A, Wolz J, Budai A, Laumeier I, Audebert HJ, Michelson G. The role of retinal vascular density as a screening tool for ageing and stroke. *Opthalmic Res.* 2020;129:103969.

25. Watanabe WR, Ye H, Peng C, et al. Retinal microvascular impairment in the early stages of Parkinson's disease. *Invest Ophthalmol Vis Sci.* 2018;59:4299–4306.

26. Chang MY, Phasukkijwatana N, Garrity S, et al. Foveal and peripapillary vascular decrement in migraine with aura demonstrated by optical coherence tomography angiography. *Invest Ophthalmol Vis Sci.* 2017;58:5477–5484.

27. Yu J, Xiao K, Huang J, Sun X, Jiang C. Reduced retinal vessel density in obstructive sleep apnea syndrome patients: an optical coherence tomography angiography study. *Invest Ophthalmol Vis Sci.* 2017;58:5306–5312.

28. Nuttall FQ. Body mass index: obesity, BMI, and health: a critical review. *Nutr Today.* 2015;50:117–128.

29. Tokayer J, Jia Y, Dhalla AH, Huang D. Blood flow velocity quantification using split-spectrum amplitude-decorrelation angiography with optical coherence tomography. *Biomed Opt Express.* 2013;4:1909–1924.

30. Akay F, Gundogan FC, Yolcu U, Toyran S, Tunc E, Uzun S. Retinal structural changes in systemic arterial hypertension: an OCT study. *Eur J Ophthal mol.* 2016;26:436–441.

31. Yu PK, Cringle SJ, Yu DY. Correlation between the radial peripapillary capillaries and the retinal nerve fibre layer in the normal human retina. *Exp Eye Res.* 2014;129:83–92.

32. Muoio V, Persson PB, Sendeski MM. The neurovascular unit - concept review. *Acta Physiol (Oxf).* 2014;210:790–798.

33. Morrison HW, Filosa JA. Stroke and the neurovascular unit: glial cells, sex differences, and hypertension. *Am J Physiol Cell Physiol.* 2019;316:C325–C339.

34. Faraco G, Sugiyama Y, Lane D, et al. Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension. *J Clin Invest.* 2016;126:4674–4689.

35. Setiadi A, Korim WS, Elsaafien K, Yao ST. The role of the blood-brain barrier in hypertension. *Exp Physiol.* 2018;103:337–342.

36. Lee JW, Park KH, Kim MS, Kim JM. Localized retinal nerve fiber layer defects associated with cotton wool spots. *Jpn J Ophthal mol.* 2010;54:296–299.

37. Lee MW, Lee WH, Park GS, Lim HB, Kim JY. Longitudinal changes in the peripapillary retinal nerve fiber layer thickness in hypertension: a 4-year prospective observational study. *Invest Ophthalmol Vis Sci.* 2019;60:3914–3919.

38. Jung S, Bosch A, Kohler N, et al. Evidence of neurodegeneration in individuals with only mildly elevated blood pressure. *J Hypertens.* 2019;37:2389–2397.

39. Poplin R, Varadarajan AV, Blumer K, et al. Prediction of cardiovascular risk factors from retinal fundus photographs via deep learning. *Nat Biomed Eng.* 2018;2:158–164.

40. Farag E, Sessler DI, Ebrahim Z, et al. The renin angiotensin system and the brain: new developments. *J Clin Neurosci.* 2017;46:1–8.

41. Caballero-Gonzalez FJ. Calcium channel blockers in the management of hypertension in the elderly. *Cardiovasc Hematol Agents Med Chem.* 2015;12:160–165.

42. Diaz JR, Kim KJ, Brands MW, Filosa JA. Augmented astrocyte microdomain Ca(2+) dynamics and parenchymal arteriole tone in angiotensin II-infused hypertensive mice. *Glia.* 2019;67:551–565.

43. Weir MR, Bakris GL. Combination therapy with renin-angiotensin-aldosterone receptor blockers for hypertension: how far have we come? *J Clin Hypertens (Greenwich).* 2008;10:146–152.